{"disease":{"id":"plaque","name":"plaque"},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"ustekinumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stelara","generic_name":"ustekinumab","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"p40 protein subunit of IL-12 and IL-23","drug_class":"","quality_score":63,"revenue":"9500","mechanism":"Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation."},{"drug_id":"risankizumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skyrizi","generic_name":"RISANKIZUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Interleukin-23 subunit alpha","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":"8600","mechanism":"Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response."},{"drug_id":"chembl-chembl1201581","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"INFLIXIMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":73,"revenue":"4200","mechanism":"Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage."},{"drug_id":"secukinumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosentyx","generic_name":"secukinumab","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Interleukin-17A (IL-17A)","drug_class":"IL-17A antagonist","quality_score":10,"revenue":"3900","mechanism":"Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor."},{"drug_id":"guselkumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tremfya","generic_name":"GUSELKUMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"p19 subunit of IL-23","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":"3600","mechanism":"Guselkumab binds to IL-23's p19 subunit, blocking its interaction with the IL-23 receptor and inhibiting proinflammatory cytokine release."},{"drug_id":"etanercept","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enbrel","generic_name":"etanercept","company_name":"Immunex","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":77,"revenue":"3100","mechanism":"Enbrel works by binding to tumor necrosis factor, a protein that promotes inflammation, thereby reducing inflammation and alleviating symptoms."},{"drug_id":"dimethyl-fumarate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tecfidera","generic_name":"DIMETHYL FUMARATE","company_name":"Biogen","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"dimethyl fumarate","quality_score":59,"revenue":"2800","mechanism":"Tecfidera works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce inflammation and modulate the immune system."},{"drug_id":"desonide","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"ixekizumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taltz","generic_name":"ixekizumab","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Interleukin 17A (IL-17A) cytokine","drug_class":"Interleukin-17A antagonist","quality_score":82,"revenue":"2700","mechanism":"Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor."},{"drug_id":"apremilast","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Otezla","generic_name":"APREMILAST","company_name":"Amgen","drug_phase":"marketed","molecular_target":"PDE4","drug_class":"Phosphodiesterase 4 Inhibitor [EPC]","quality_score":71,"revenue":"2100","mechanism":"Apremilast inhibits PDE4, increasing intracellular cAMP levels, but the exact therapeutic mechanism is unclear."},{"drug_id":"certolizumab-pegol","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cimzia","generic_name":"CERTOLIZUMAB PEGOL","company_name":"UCB","drug_phase":"marketed","molecular_target":"TNFα","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":68,"revenue":"1600","mechanism":"Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity."},{"drug_id":"bimekizumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bimzelx","generic_name":"BIMEKIZUMAB","company_name":"Ucb Japan Co., Ltd.","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":55,"revenue":"1200","mechanism":"Bimzelx works by binding to interleukin-17A, a protein that promotes inflammation, to reduce symptoms of psoriasis."},{"drug_id":"infliximab-infliximab-biosimilar-3","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infliximab [infliximab biosimilar 3]","generic_name":"infliximab-infliximab-biosimilar-3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor-alpha (TNF-alpha)","drug_class":"monoclonal antibody","quality_score":10,"revenue":"646","mechanism":"Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions."},{"drug_id":"tildrakizumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunpg 1622","generic_name":"TILDRAKIZUMAB","company_name":"Sun Pharma Global","drug_phase":"marketed","molecular_target":"Interleukin-23","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":"500","mechanism":"Tildrakizumab blocks the action of Interleukin-23, a protein that promotes inflammation."},{"drug_id":"tildrakizumab","indication_name":"Moderate-to-severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunpg 1622","generic_name":"TILDRAKIZUMAB","company_name":"Sun Pharma Global","drug_phase":"marketed","molecular_target":"Interleukin-23","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":"500","mechanism":"Tildrakizumab blocks the action of Interleukin-23, a protein that promotes inflammation."},{"drug_id":"deucravacitinib","indication_name":"Moderate-to-severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sotyktu","generic_name":"DEUCRAVACITINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Non-receptor tyrosine-protein kinase TYK2","drug_class":"Tyrosine Kinase 2 Inhibitor [EPC]","quality_score":69,"revenue":"291","mechanism":"Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis."},{"drug_id":"deucravacitinib","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sotyktu","generic_name":"DEUCRAVACITINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Non-receptor tyrosine-protein kinase TYK2","drug_class":"Tyrosine Kinase 2 Inhibitor [EPC]","quality_score":69,"revenue":"291","mechanism":"Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis."},{"drug_id":"fluticasone-propionate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"clobetasol-propionate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temovate","generic_name":"CLOBETASOL PROPIONATE","company_name":"Fougera Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"desoximetasone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topicort","generic_name":"DESOXIMETASONE","company_name":"Taro","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluocinolone-acetonide","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"clocortolone-pivalate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cloderm","generic_name":"CLOCORTOLONE PIVALATE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"ulobetasol-propionate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":10,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"betamethasone-dipropionate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprolene","generic_name":"BETAMETHASONE DIPROPIONATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system."},{"drug_id":"otezla","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Otezla","company_name":"L.H. Kircik, M.D.","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4C","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"betamethasone-valerate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone Valerate","generic_name":"BETAMETHASONE VALERATE","company_name":"Fougera Pharms Inc","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"delmopinol","indication_name":"Dental plaque","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decapinol","generic_name":"DELMOPINOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"delmopinol","quality_score":null,"revenue":null,"mechanism":"Decapinol works by preventing the adhesion of bacteria to tooth surfaces."},{"drug_id":"calcipotriene","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dovonex","generic_name":"CALCIPOTRIENE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D Analog [EPC]","quality_score":58,"revenue":null,"mechanism":"Calcipotriene works by binding to the Vitamin D3 receptor, which helps to regulate the growth of skin cells and reduce inflammation."},{"drug_id":"adalimumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Moderate to Severe Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"calcipotriol","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"calcipotriol","company_name":"NeoStrata Company, Inc.","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"trientine","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Syprine","generic_name":"TRIENTINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 14","drug_class":"Copper Chelator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"infliximab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"infliximab","company_name":"Johnson & Johnson","drug_phase":"discontinued","molecular_target":"TNFα","drug_class":"Monoclonal antibody","quality_score":43,"revenue":null,"mechanism":"Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses."},{"drug_id":"remicade","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Remicade","company_name":"Shanghai Biomabs Pharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"inflectra","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remicade","generic_name":"Infliximab-Dyyb","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor alpha (TNFα)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding."},{"drug_id":"adalimumab-adbm","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"tildrakizumab-asmn","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ILUMYA","generic_name":"TILDRAKIZUMAB-ASMN","company_name":"SUN PHARMA GLOBAL","drug_phase":"marketed","molecular_target":"Interleukin-23","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"infliximab-qbtx","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"IXIFI","generic_name":"INFLIXIMAB-QBTX","company_name":"PFIZER INC","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"taltz","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taltz","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"bimekizumab-bkzx","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BIMZELX","generic_name":"BIMEKIZUMAB-BKZX","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"Interleukin-17A, Interleukin-17F, Interleukin-17AF","drug_class":"","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"nasonex","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"betamethasone-benzoate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone 17-Benzoate","generic_name":"BETAMETHASONE BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tacalcitol","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TACALCITOL","company_name":"","drug_phase":"phase_3","molecular_target":"Vitamin D3 receptor","drug_class":"tacalcitol","quality_score":null,"revenue":null,"mechanism":"TACALCITOL works by binding to the Vitamin D3 receptor, which helps to reduce inflammation and modulate the immune response."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to Severe Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"triamcinolone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"flixotide","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"anti-beta-interferon-pf-06823859","indication_name":"Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anti-Beta Interferon (PF-06823859)","generic_name":"anti-beta-interferon-pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta interferon","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"fluocinonide","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lidex","generic_name":"FLUOCINONIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"calcitriol","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calcijex","generic_name":"CALCITRIOL","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"Vitamin D3 receptor","drug_class":"Vitamin D3 Analog [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"halcinonide","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halog","generic_name":"HALCINONIDE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"prednicarbate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dermatop","generic_name":"PREDNICARBATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"efalizumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu1124","generic_name":"EFALIZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"Leukocyte adhesion glycoprotein LFA-1 alpha","drug_class":"CD11a-directed Humanized IgG1 Antibody","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"alefacept","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amevive","generic_name":"ALEFACEPT","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"T-cell surface antigen CD2","drug_class":"CD2-directed LFA-3/Fc Fusion Protein","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"ulobetasol-propionate","indication_name":"Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":10,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mometasone-furoate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"diflorasone-diacetate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Psorcon","generic_name":"DIFLORASONE DIACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"amcinonide","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclocort","generic_name":"AMCINONIDE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"methotrexate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"methotrexat","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tild","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TILD","company_name":"Sun Pharmaceutical Industries Limited","drug_phase":"marketed","molecular_target":"Interleukin-23","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Tild is a small molecule that works by interacting with a specific target in the body."},{"drug_id":"cimzia","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cimzia","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daxas","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daxas","company_name":"AstraZeneca","drug_phase":"phase_2","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humira","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rocaltrol","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rocaltrol","company_name":"Shandong University","drug_phase":"marketed","molecular_target":"Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amevive","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amevive","company_name":"University Hospitals Cleveland Medical Center","drug_phase":"discontinued","molecular_target":"T-cell surface antigen CD2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tecfidera","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tecfidera","company_name":"EMD Serono Research & Development Institute, Inc.","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enbrel","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enbrel","company_name":"LG Life Sciences","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mometasone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ustekinumab-aekn","indication_name":"Moderate to Severe Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SELARSDI","generic_name":"USTEKINUMAB-AEKN","company_name":"ALVOTECH USA INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"bimekizumab-bkzx","indication_name":"Moderate to severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BIMZELX","generic_name":"BIMEKIZUMAB-BKZX","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"Interleukin-17A, Interleukin-17F, Interleukin-17AF","drug_class":"","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-aqvh","indication_name":"Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"YUSIMRY","generic_name":"ADALIMUMAB-AQVH","company_name":"COHERUS BIOSCIENCES INC","drug_phase":"marketed","molecular_target":"","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ustekinumab-auub","indication_name":"Moderate to Severe Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"WEZLANA","generic_name":"USTEKINUMAB-AUUB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Interleukin-12 Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"drug-abatacept","indication_name":"Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"mouth-rinse","indication_name":"Control of plaque leading to bleeding gums","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"mouth rinse","company_name":"Ministry of Higher Education, Malaysia","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"drug-abatacept","indication_name":"Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"flumetasone","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flucorticin","generic_name":"flumetasone","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"flumetasone","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"cosentyx","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cosentyx","company_name":"Janssen Research & Development, LLC","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"alclometasone-dipropionate","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclovate","generic_name":"ALCLOMETASONE DIPROPIONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"stelara","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stelara","company_name":"Biocon Biologics UK Ltd","drug_phase":"marketed","molecular_target":"Interleukin-12, Interleukin-23","drug_class":"","quality_score":30,"revenue":null,"mechanism":"Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Moderate to Severe Plaque Psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"raptiva","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Raptiva","company_name":"National Institute of Dental and Craniofacial Research (NIDCR)","drug_phase":"discontinued","molecular_target":"Leukocyte adhesion glycoprotein LFA-1 alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"fludroxycortide","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordran","generic_name":"fludroxycortide","company_name":"Aqua Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"brodalumab","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kyntheum","generic_name":"BRODALUMAB","company_name":"Valeant Luxembourg","drug_phase":"marketed","molecular_target":"Interleukin-17 receptor","drug_class":"Interleukin-17 Receptor A Antagonist [EPC]","quality_score":55,"revenue":null,"mechanism":"Kyntheum works by blocking the interleukin-17 receptor, a protein that plays a key role in inflammation."},{"drug_id":"roflumilast","indication_name":"Plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daliresp","generic_name":"ROFLUMILAST","company_name":"Arcutis","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"Phosphodiesterase 4 Inhibitor [EPC]","quality_score":63,"revenue":null,"mechanism":"Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body."}],"pipeline":[{"drug_id":"pf-07038124","indication_name":"Plaque Psoriasis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07038124","generic_name":"pf-07038124","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphodiesterase-4 (PDE4)","drug_class":"Phosphodiesterase-4 inhibitor","quality_score":25,"revenue":null,"mechanism":"PF-07038124 is a topical PDE4 inhibitor that blocks phosphodiesterase-4 to reduce inflammatory cytokine production in skin immune cells."}],"offLabel":[],"totalMarketed":122,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07212751","title":"Coronary CT Angiogram - Prognostic Value of Adverse Plaque Features in Guiding Treatment (CT-PLAQUE)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06933745","title":"Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":21029,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT02409667","title":"Plaque Psoriasis Efficacy and Safety With Secukinumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16487,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT00799877","title":"Chronic Plaque Psoriasis (Ps) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":6065,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT01077232","title":"Documentation of Humira in Psoriasis Patients in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":5442,"lead_sponsor_name":"AbbVie (prior sponsor, Abbott)","has_results":false},{"nct_id":"NCT04614831","title":"A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":4978,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06523712","title":"A Scalable, Teacher-delivered, School-based Oral Health Intervention for Pakistani Lower Secondary Schoolchildren","phase":"NA","overall_status":"COMPLETED","enrollment_count":4055,"lead_sponsor_name":"Universiti Putra Malaysia","has_results":false},{"nct_id":"NCT07116967","title":"Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3040,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05843487","title":"Association Between Carotid Plaque Length and Cardiovascular Outcomes","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT05594004","title":"A Meta-analysis Comparing Toothbrushes on Plaque Removal and Gingival Health","phase":"","overall_status":"COMPLETED","enrollment_count":2929,"lead_sponsor_name":"Procter and Gamble","has_results":false},{"nct_id":"NCT03982394","title":"Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis","phase":"","overall_status":"COMPLETED","enrollment_count":2759,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04006483","title":"Meta-analysis of Stannous Fluoride and the Effects on Dental Plaque","phase":"","overall_status":"COMPLETED","enrollment_count":2359,"lead_sponsor_name":"Procter and Gamble","has_results":false},{"nct_id":"NCT06855537","title":"Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2190,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT04017507","title":"The Effects of Oscillating-Rotating Electric Toothbrushes on Plaque and Gingival Health","phase":"","overall_status":"COMPLETED","enrollment_count":2145,"lead_sponsor_name":"Procter and Gamble","has_results":false},{"nct_id":"NCT04001296","title":"The Impact of a 21day School Brushing Intervention on the Knowledge, Behaviour and Oral Health of School Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":2020,"lead_sponsor_name":"Unilever R&D","has_results":false},{"nct_id":"NCT06025305","title":"Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT06550076","title":"A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1950,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02360137","title":"Atherosclerotic Plaque Characteristics Associated With a Progression Rate of the Plaque in Carotids and a Risk of Stroke","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1863,"lead_sponsor_name":"University Hospital Ostrava","has_results":false},{"nct_id":"NCT02752776","title":"A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1660,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02316886","title":"Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1608,"lead_sponsor_name":"Seung-Jung Park","has_results":false},{"nct_id":"NCT03703245","title":"Pooled Analysis of Clinical Data From Six GSK Studies to Investigate the Efficacy of a Dentifrice Containing 67% Weight by Weight (w/w) Sodium Bicarbonate on Gingivitis and Plaque Accumulation","phase":"","overall_status":"COMPLETED","enrollment_count":1601,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02486302","title":"A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.","phase":"","overall_status":"COMPLETED","enrollment_count":1534,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03598790","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1353,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT05333068","title":"COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1222,"lead_sponsor_name":"Diagram B.V.","has_results":false},{"nct_id":"NCT07466251","title":"PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1212,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT01544595","title":"Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1147,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02114372","title":"Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":1136,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02274363","title":"A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis","phase":"","overall_status":"COMPLETED","enrollment_count":1131,"lead_sponsor_name":"Janssen Pharmaceutica","has_results":false},{"nct_id":"NCT02826603","title":"Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1114,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06108544","title":"A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1108,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01729754","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1090,"lead_sponsor_name":"Sun Pharmaceutical Industries Limited","has_results":true},{"nct_id":"NCT03573323","title":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1027,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT06187532","title":"Carotid Plaque-Burden Scale and Outcomes. A Real Life Study","phase":"","overall_status":"COMPLETED","enrollment_count":1004,"lead_sponsor_name":"Fundación para la Formación e Investigación de los Profesionales de la Salud de Extremadura","has_results":false},{"nct_id":"NCT05621369","title":"Psorcast Mobile Study","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Sage Bionetworks","has_results":false},{"nct_id":"NCT03314818","title":"Natural History of Carotid Plaque as Determined by 3D Ultrasound","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Pieter Muntendam","has_results":false},{"nct_id":"NCT06802848","title":"Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chongqing Genrix Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03702764","title":"Coronary Plaque Geometry and Acute Coronary Syndromes","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Cardio Med Medical Center","has_results":false},{"nct_id":"NCT05509361","title":"Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":950,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06586112","title":"A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":912,"lead_sponsor_name":"Alumis Inc","has_results":false},{"nct_id":"NCT02239666","title":"Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis","phase":"","overall_status":"COMPLETED","enrollment_count":899,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06588738","title":"A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":862,"lead_sponsor_name":"Alumis Inc","has_results":false},{"nct_id":"NCT02886702","title":"A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":855,"lead_sponsor_name":"Fougera Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT01194219","title":"Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":844,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05619042","title":"Detection of Coronary Artery Calcifications by Whole Blood Transcriptome Analyzed by Artificial InTelligence Algorithms","phase":"","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Santiago Gabriel Miriuka","has_results":false},{"nct_id":"NCT03726489","title":"Light Treatment Effectiveness (LITE) Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT04823247","title":"Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study","phase":"","overall_status":"COMPLETED","enrollment_count":782,"lead_sponsor_name":"Almirall, S.A.","has_results":false},{"nct_id":"NCT06143878","title":"A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":774,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02474069","title":"Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":772,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01722331","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":772,"lead_sponsor_name":"Sun Pharmaceutical Industries Limited","has_results":true},{"nct_id":"NCT05368818","title":"An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source","phase":"","overall_status":"COMPLETED","enrollment_count":767,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}